IL6 and plasma cell myeloma: IL−6 is one of the most well-known pro-myeloma adipokines, and targeting of IL6 signaling is under clinical investigation with monoclonal antibodies to IL−6 (siltuximab) or the IL−6 receptor (tocilizumab) [59].